Other
Center for Research and Production of Vaccines and Biologicals, Vietnam
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed trials have results
Key Signals
1 with results
Enrollment Performance
Analytics
Phase 3
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 3(2)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT03703336Phase 3Completed
Phase III Study of Liquid Formulation of ROTAVIN
Role: lead
NCT03713359Phase 3Completed
Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (Phase III)
Role: lead
NCT01377571Phase 2Completed
A Dose-escalating Study to Evaluate the Immunogenicity and Safety of Rotavin-M1 Vaccine in Healthy Infants
Role: collaborator
All 3 trials loaded